- Flamma has inaugurated a new cGMP manufacturing plant in Dalian, China, expanding its small molecule API production capabilities.
- The investment forms part of a $200 million global strategy to scale operations across China and Italy.
Flamma, a global contract development and manufacturing organisation (CDMO), has announced the grand opening of a new current Good Manufacturing Practice (cGMP) facility in Dalian, China. The plant will enhance the company’s capacity to produce and commercialise small molecule active pharmaceutical ingredients (APIs) for innovator clients worldwide.
The opening marks a strategic milestone in Flamma’s global expansion, complementing its long-standing operations in Italy. Founded 75 years ago in Bergamo, Italy, Flamma has developed a fully integrated global network. The new Dalian site is part of a $200 million investment plan to expand manufacturing capacity and technological capabilities over the next five years.
Flamma has had a presence in China for over three decades, initially sourcing raw materials and later expanding into research and development. In 2012, it established Flamma Honkai, a wholly owned subsidiary in Dalian. “With Honkai being a fully owned and run subsidiary, we’ve been able to combine Flamma’s core values and expertise with the efficiency of the Honkai management team,” said Dr. GianPaolo Negrisoli, President and CEO.
The Dalian operations have seen substantial growth, achieving Chinese FDA approval and a 30-fold increase in turnover. The new facility strengthens Flamma’s CDMO offering for new chemical entities (NCEs) and late-stage intermediates.
“Our global expansion complements the substantial investments we are making in Italy,” added GianMarco Negrisoli, Executive Director – Corporate Development. The company continues to scale its facilities and talent base, reinforcing the synergy between Italian manufacturing excellence and a global outlook.
